John Harrington
Plus aucun poste en cours
Fortune : 163 $ au 31/03/2024
Profil
John J.
Harrington is the founder of Athersys, Inc. which was founded in 1995.
He held the title of Director, Chief Scientific Officer & Executive VP from 1995 to 2022.
He also founded Athersys, Inc. in 2007.
Dr. Harrington's former job was as Chief Scientific Officer & EVP at BTHC VI, Inc. Dr. Harrington received a doctorate degree from Stanford University and an undergraduate degree from the University of California San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ATHERSYS, INC.
0,04% | 14/08/2023 | 27 169 ( 0,04% ) | 163 $ | 31/03/2024 |
Anciens postes connus de John Harrington
| Sociétés | Poste | Fin |
|---|---|---|
| ATHERSYS, INC. | Founder | 16/06/2022 |
| BTHC VI, Inc. | Chief Tech/Sci/R&D Officer | 06/09/2007 |
Athersys, Inc. /Old/
 Athersys, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Athersys, Inc. manufactures & markets pharmaceutical products and is engaged in the development and commercialization of therapeutic products to treat significant and life-threatening diseases. The company has three primary focus areas, which include: regenerative medicine (applying the MultiStem, cell therapy platform), medicinal chemistry & pharmacology genomics. It was founded in December 1995 and is headquartered at Cleveland, OH. | Founder | 08/06/2007 |
Formation de John Harrington
| Stanford University | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ATHERSYS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Athersys, Inc. /Old/
Athersys, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Athersys, Inc. manufactures & markets pharmaceutical products and is engaged in the development and commercialization of therapeutic products to treat significant and life-threatening diseases. The company has three primary focus areas, which include: regenerative medicine (applying the MultiStem, cell therapy platform), medicinal chemistry & pharmacology genomics. It was founded in December 1995 and is headquartered at Cleveland, OH. | Health Technology |
| BTHC VI, Inc. | Finance |
